50% Gains Are Possible For This $7B Medtech Stock

A leader in diagnostic testing looks attractive after sell-off

Highlights:

• This business exploded during the pandemic thanks to COVID testing revenue. But the business was performing well before then.

• With COVID revenue bottoming, strength in a historically attractive business is about to shine through.

• We think the stock has 50% upside in a conservative scenario, making it more than worth the risk near the lows.